O-8 Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150
D. Li, Han Chong Toh, Philippe Merle, Kaoru Tsuchiya, Sairy Hernandez, Hui Shao, S. Mulla, Beiying Ding, Masatoshi Kudo
Topics & Concepts
MedicineAtezolizumabBevacizumabSorafenibInternal medicineClinical endpointHepatocellular carcinomaOncologyAdverse effectResponse Evaluation Criteria in Solid TumorsPhases of clinical researchRandomized controlled trialClinical trialQuality of life (healthcare)CancerChemotherapyNivolumabImmunotherapyNursingColorectal Cancer Treatments and StudiesHepatocellular Carcinoma Treatment and PrognosisLung Cancer Treatments and Mutations